Advances in CRISPR-Cas system-based detection of Mycobacterium tuberculosis

doi:10.19982/j.issn.1000-6621.20250449

Abstract

Abstract:

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), poses a severe threat to global public health security. However, traditional MTB detection methods, such as smear microscopy and bacterial culture, suffer from insufficient sensitivity, prolonged turnaround times, and delayed drug resistance detection, which have constrained the achievement of the World Health Organization (WHO)’s “End TB” strategy. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, characterized by high specificity and rapidity, offers transformative potential for MTB testing. This review systematically outlines the latest research progress of CRISPR in MTB point-of-care testing, drug resistance gene detection, and multi-target combined testing. It highlights key challenges in current research, including complex sample pretreatment, poor reagent stability, and inadequate adaptability to primary healthcare settings. Future efforts should focus on simplifying and integrating sample pretreatment and optimizing reagent lyophilization techniques, aiming to provide references for the clinical translation of CRISPR-based MTB detection and the precise prevention and control of TB.

Key words: Mycobacterium tuberculosis, CRISPR-Cas system, Diagnose technology, Molecular diagnostic techniques

CLC Number:

Huang Zhenyang, Li Wenjun, Sun Yansong, Li Hao. Advances in CRISPR-Cas system-based detection of Mycobacterium tuberculosis[J]. Chinese Journal of Antituberculosis, 2026, 48(5): 707-715. doi: 10.19982/j.issn.1000-6621.20250449

Figures/Tables 1

References 82

[1]	Chen X, Huang J, Xiao Z, et al. Highly specific and sensitive detection of the Mycobacterium tuberculosis complex using multiplex loop-mediated isothermal amplification combined with a nanoparticle-based lateral flow biosensor. Braz J Microbiol, 2021, 52(3): 1315-1325. doi:10.1007/s42770-021-00520-4. pmid: 34176103
[2]	王小敏, 陈锦云, 曾昱芹, 等. 《世界卫生组织结核病整合指南模块3:诊断——结核病检测的快速诊断》第三版解读. 中国防痨杂志, 2024, 46(9): 1006-1022. doi:10.19982/j.issn.1000-6621.20240221.
[3]	Allemailem KS, Almatroudi A, Alrumaihi F, et al. Current Updates of CRISPR/Cas System and Anti-CRISPR Proteins: Innovative Applications to Improve the Genome Editing Strategies. Int J Nanomedicine, 2024, 19: 10185-10212. doi:10.2147/ijn.S479068.
[4]	Lin Z, Song Z, Yu H, et al. Ultra-sensitive in situ detection of intracellular Mycobacterium tuberculosis with CRISPR/Cas12a. Front Immunol, 2025, 16: 1597654. doi:10.3389/fimmu.2025.1597654.
[5]	Liu S, Xiao G, Li P, et al. Plasma-based ultrasensitive detection of Mycobacterium tuberculosis ESAT6/CFP10 fusion antigen using a CRISPR-driven aptamer fluorescence testing (CRAFT). Biosens Bioelectron, 2025, 284: 117566. doi:10.1016/j.bios.2025.117566.
[6]	Huang Z, Song Z, Zeng J, et al. Sensitive pathogen DNA detection by a multi-guide RNA Cas12a assay favoring trans-versus cis-cleavage. Nat Commun, 2025, 16(1): 8257. doi:10.1038/s41467-025-63094-x.
[7]	Huang Z, Zhang G, Lyon CJ, et al. Outlook for CRISPR-based tuberculosis assays now in their infancy. Front Immunol, 2023, 14: 1172035. doi:10.3389/fimmu.2023.1172035.
[8]	Tong X, Zhang K, Han Y, et al. Fast and sensitive CRISPR detection by minimized interference of target amplification. Nat Chem Biol, 2024, 20(7): 885-893. doi:10.1038/s41589-023-01534-9. pmid: 38332130
[9]	Zein-Eddine R, Refrégier G, Cervantes J, et al. The future of CRISPR in Mycobacterium tuberculosis infection. J Biomed Sci, 2023, 30(1): 34. doi:10.1186/s12929-023-00932-4. pmid: 37245014
[10]	Sodani M, Misra CS, Kulkarni S, et al. CRISPR/Cas12a-mediated gene silencing across diverse functional genes demonstrates single gene-specific spacer efficacy in Mycobacterium smegmatis. J Biol Eng, 2025, 19(1): 21. doi:10.1186/s13036-025-00490-3. pmid: 40022115
[11]	Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 2017, 356(6336): 438-442. doi:10.1126/science.aam9321. pmid: 28408723
[12]	Chen JS, Ma E, Harrington LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 2018, 360(6387): 436-439. doi:10.1126/science.aar6245. pmid: 29449511
[13]	Li SY, Cheng QX, Wang JM, et al. CRISPR-Cas12a-assisted nucleic acid detection. Cell Discov, 2018, 4: 20. doi:10.1038/s41421-018-0028-z.
[14]	Pei S, Song Z, Yang W, et al. The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis. Lancet Microbe, 2024, 5(11): 100899. doi:10.1016/s2666-5247(24)00131-9.
[15]	Domínguez J, Boeree MJ, Cambau E, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis, 2023, 23(4): e122-e137. doi:10.1016/s1473-3099(22)00875-1.
[16]	Li X, Liu J, Wang R, et al. CRISPR-based one-pot detection: A game-changer in nucleic acid analysis. Biosens Bioelectron, 2025, 288: 117786. doi:10.1016/j.bios.2025.117786.
[17]	Chen L, Hu M, Zhou X. Trends in developing one-pot CRISPR diagnostics strategies. Trends Biotechnol, 2025, 43(1): 98-110. doi:10.1016/j.tibtech.2024.07.007.
[18]	Liu H, Yin H, Xiu L, et al. One-Pot Isothermal Nucleic Acid Amplification Assisted CRISPR/Cas Detection Technology: Challenges, Strategies, and Perspectives. Adv Sci (Weinh), 2025, 12(37): e06716. doi:10.1002/advs.202506716.
[19]	Peng L, Fang T, Cai Q, et al. Rapid detection of Mycobacterium tuberculosis in sputum using CRISPR-Cas12b combined with cross-priming amplification in a single reaction. J Clin Microbiol, 2024, 62(1): e0092323. doi:10.1128/jcm.00923-23.
[20]	Reddy KP, Denkinger CM, Broger T, et al. Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. Clin Infect Dis, 2021, 73(7): e2077-e2085. doi:10.1093/cid/ciaa1698.
[21]	Bell AG, Dunkley ORS, Modi NH, et al. A streamlined CRISPR-based test for tuberculosis detection directly from sputum. Sci Adv, 2025, 11(32): eadx2067. doi:10.1126/sciadv.adx2067.
[22]	Arizti-Sanz J, Freije CA, Stanton AC, et al. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat Commun, 2020, 11(1): 5921. doi:10.1038/s41467-020-19097-x. pmid: 33219225
[23]	Wang B, Wang R, Wang D, et al. Cas12aVDet: A CRISPR/Cas12a-Based Platform for Rapid and Visual Nucleic Acid Detection. Anal Chem, 2019, 91(19): 12156-12161. doi:10.1021/acs.analchem.9b01526. pmid: 31460749
[24]	Uno N, Li Z, Avery L, et al. CRISPR gel: A one-pot biosensing platform for rapid and sensitive detection of HIV viral RNA. Anal Chim Acta, 2023, 1262: 341258. doi:10.1016/j.aca.2023.341258.
[25]	Ali Z, Aman R, Mahas A, et al. iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Res, 2020, 288: 198129. doi:10.1016/j.virusres.2020.198129.
[26]	Li SY, Cheng QX, Liu JK, et al. CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA. Cell Res, 2018, 28(4): 491-493. doi:10.1038/s41422-018-0022-x.
[27]	Youngquist BM, Saliba J, Kim Y, et al. Rapid tuberculosis diagnosis from respiratory or blood samples by a low cost, portable lab-in-tube assay. Sci Transl Med, 2025, 17(793): eadp6411. doi:10.1126/scitranslmed.adp6411.
[28]	Horne DJ, Zifodya JS, Shapiro AE, et al. Xpert MTB/RIF Ultra assay for pulmonary tuberculosis and rifampicin resistance in adults and adolescents. Cochrane Database Syst Rev, 2025, 7(7): Cd009593. doi:10.1002/14651858.CD009593.pub6.
[29]	Chen H, Song F, Wang B, et al. Ultrasensitive detection of clinical pathogens through a target-amplification-free collateral-cleavage-enhancing CRISPR-CasΦ tool. Nat Commun, 2025, 16(1): 3929. doi:10.1038/s41467-025-59219-x.
[30]	Wang M, Chen M, Wu X, et al. CRISPR applications in cancer diagnosis and treatment. Cell Mol Biol Lett, 2023, 28(1): 73. doi:10.1186/s11658-023-00483-4. pmid: 37674114
[31]	Guk K, Yi S, Kim H, et al. Hybrid CRISPR/Cas protein for one-pot detection of DNA and RNA. Biosens Bioelectron, 2023, 219: 114819. doi:10.1016/j.bios.2022.114819.
[32]	Hu F, Liu Y, Zhao S, et al. A one-pot CRISPR/Cas13a-based contamination-free biosensor for low-cost and rapid nucleic acid diagnostics. Biosens Bioelectron, 2022, 202: 113994. doi:10.1016/j.bios.2022.113994.
[33]	Jiang Y, Wu J, Xiang X, et al. A cleavage-gated terminal exposure-driven CRISPR-RCA self-amplifying system for ultra-fast DNA detection. Biosens Bioelectron, 2025, 289: 117857. doi:10.1016/j.bios.2025.117857.
[34]	Singh M, Bindal G, Misra CS, et al. The era of Cas12 and Cas 13 CRISPR-based disease diagnosis. Crit Rev Microbiol, 2022, 48(6): 714-729. doi:10.1080/1040841x.2021.2025041.
[35]	Huyke DA, Ramachandran A, Bashkirov VI, et al. Enzyme Kinetics and Detector Sensitivity Determine Limits of Detection of Amplification-Free CRISPR-Cas12 and CRISPR-Cas13 Diagnostics. Anal Chem, 2022, 94(27): 9826-9834. doi:10.1021/acs.analchem.2c01670. pmid: 35759403
[36]	Ren W, Zhou Y, Li H, et al. Development and clinical evaluation of a CRISPR/Cas13a-based diagnostic test to detect Mycobacterium tuberculosis in clinical specimens. Front Microbiol, 2023, 14: 1117085. doi:10.3389/fmicb.2023.1117085.
[37]	Thakku SG, Lirette J, Murugesan K, et al. Genome-wide tiled detection of circulating Mycobacterium tuberculosis cell-free DNA using Cas13. Nat Commun, 2023, 14(1): 1803. doi:10.1038/s41467-023-37183-8.
[38]	Shihong Gao D, Zhu X, Lu B. Development and application of sensitive, specific, and rapid CRISPR-Cas13-based diagnosis. J Med Virol, 2021, 93(7): 4198-4204. doi:10.1002/jmv.26889. pmid: 33599292
[39]	World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization, 2025.
[40]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[41]	Cao G, Yang N, Xiong Y, et al. Completely Free from PAM Limitations: Asymmetric RPA with CRISPR/Cas12a for Nucleic Acid Assays. ACS Sens, 2023, 8(12): 4655-4663. doi:10.1021/acssensors.3c01686.
[42]	白晓鹏. 基于Cas13a的结核分枝杆菌氟喹诺酮药耐受相关突变的快速检测技术. 重庆: 重庆医科大学, 2021.
[43]	Yang J, Li X, He Q, et al. Structural basis for the activity of the type Ⅶ CRISPR-Cas system. Nature, 2024, 633(8029): 465-472. doi:10.1038/s41586-024-07815-0.
[44]	Li W, Jiang X, Wang W, et al. Discovering CRISPR-Cas system with self-processing pre-crRNA capability by foundation models. Nat Commun, 2024, 15(1): 10024. doi:10.1038/s41467-024-54365-0.
[45]	Lai Y, Guo K, Zhu C, et al. Cas14VIDet: A visual instant method free from PAM restriction for antibiotic resistance bacteria detection. Biosens Bioelectron, 2025, 268: 116884. doi:10.1016/j.bios.2024.116884.
[46]	王苑柠, 杜宗敏. CRISPR/Cas分子诊断技术在结核分枝杆菌耐药性检测中的研究进展. 中国防痨杂志, 2025, 47(5): 666-672. doi:10.19982/j.issn.1000-6621.20240523.
[47]	Xiao G, Liu H, Xu H, et al. Direct detection from sputum for drug-resistant Mycobacterium tuberculosis using a CRISPR-Cas14a-based approach. BMC Microbiol, 2025, 25(1): 188. doi:10.1186/s12866-025-03899-4.
[48]	Zhou X, Han X, Liu L, et al. Cas12b-assisted one-step dual-target CRISPR system for Mycobacterium tuberculosis detection. Biosensors and Bioelectronics: X, 2025, 27: 100692. doi:10.1016/j.biosx.2025.100692.
[49]	Olbrich L, Franckling-Smith Z, Larsson L, et al. Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study. Lancet Infect Dis, 2025, 25(2): 188-197. doi:10.1016/s1473-3099(24)00494-8.
[50]	Freitag B, Sultanli A, Grilli M, et al. Clinically diagnosed tuberculosis and mortality in high burden settings: a systematic review and meta-analysis. EClinicalMedicine, 2025, 84: 103251. doi:10.1016/j.eclinm.2025.103251.
[51]	Baik Y, Rickman HM, Hanrahan CF, et al. A clinical score for identifying active tuberculosis while awaiting microbiological results: Development and validation of a multivariable prediction model in sub-Saharan Africa. PLoS Med, 2020, 17(11): e1003420. doi:10.1371/journal.pmed.1003420.
[52]	Kokuto H, Sasaki Y, Yoshimatsu S, et al. Detection of Mycobacterium tuberculosis (MTB) in Fecal Specimens From Adults Diagnosed With Pulmonary Tuberculosis Using the Xpert MTB/Rifampicin Test. Open Forum Infect Dis, 2015, 2(2): ofv074. doi:10.1093/ofid/ofv074.
[53]	Paris L, Magni R, Zaidi F, et al. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity. Sci Transl Med, 2017, 9(420): eaal2807. doi:10.1126/scitranslmed.aal2807.
[54]	Lopez AL, Aldaba JG, Morales-Dizon M, et al. Urine Xpert MTB/RIF for the diagnosis of childhood tuberculosis. Int J Infect Dis, 2019, 79: 44-46. doi:10.1016/j.ijid.2018.11.013. pmid: 30496848
[55]	Vogt SL, Patel M, Lakha A, et al. Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma. JCO Glob Oncol, 2021, 7: 611-621. doi:10.1200/go.20.00651. pmid: 33909482
[56]	Pohl C, Rutaihwa LK, Haraka F, et al. Limited value of whole blood Xpert(®) MTB/RIF for diagnosing tuberculosis in children. J Infect, 2016, 73(4): 326-335. doi:10.1016/j.jinf.2016.04.041. pmid: 27394403
[57]	Mosquera-Restrepo SF, Zuberogoïtia S, Gouxette L, et al. A Mycobacterium tuberculosis fingerprint in human breath allows tuberculosis detection. Nat Commun, 2022, 13(1): 7751. doi:10.1038/s41467-022-35453-5. pmid: 36517492
[58]	Wood RC, Luabeya AK, Dragovich RB, et al. Tongue swab testing on two automated tuberculosis diagnostic platforms, Cepheid Xpert(®) MTB/RIF Ultra and Molbio Truenat(®) MTB Ultima. J Clin Microbiol, 2024, 62(4): e0001924. doi:10.1128/jcm.00019-24.
[59]	Wood RC, Luabeya AK, Weigel KM, et al. Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients. Sci Rep, 2015, 5: 8668. doi:10.1038/srep08668.
[60]	Rockman L, Abdulgader SM, Minnies S, et al. Oral washes and tongue swabs for Xpert MTB/RIF Ultra-based tuberculosis diagnosis in people with and without the ability to make sputum. Clin Infect Dis, 2026, 81(6):e632-e642. doi:10.1093/cid/ciaf397.
[61]	Bezuidenhout C, Long L, Nichols B, et al. Using sputum and tongue swab specimens for in-home point-of-care targeted universal testing for TB of household contacts: an acceptability and feasibility analysis. BMJ Glob Health, 2025, 10(8):e018131. doi:10.1136/bmjgh-2024-018131.
[62]	Wang Y, Cui J, Li Y, et al. Rapid quantitative PCR on tongue swabs for pulmonary tuberculosis in adults: a prospective multicentre study. Eur Respir J, 2025, 65(1):2401493. doi:10.1183/13993003.01493-2024.
[63]	夏强. 基于序列特异性DNA结合蛋白靶向捕获DNA的研究. 南京:东南大学, 2019.
[64]	Mizuguchi T, Toyota T, Miyatake S, et al. Complete sequencing of expanded SAMD12 repeats by long-read sequencing and Cas9-mediated enrichment. Brain, 2021, 144(4): 1103-1117. doi:10.1093/brain/awab021. pmid: 33791773
[65]	田甜, 周小明. 基于CRISPR/Cas9的基因分析方法研究进展. 激光生物学报, 2020, 29(1):18-25. doi:10.3969/j.issn.1007-7146.2020.01.003.
[66]	Lee J, Lim H, Jang H, et al. CRISPR-Cap: multiplexed double-stranded DNA enrichment based on the CRISPR system. Nucleic Acids Res, 2019, 47(1): e1. doi:10.1093/nar/gky820.
[67]	Jiang W, Zhu TF. Targeted isolation and cloning of 100-kb microbial genomic sequences by Cas9-assisted targeting of chromosome segments. Nat Protoc, 2016, 11(5): 960-975. doi:10.1038/nprot.2016.055. pmid: 27101517
[68]	Tram TTB, Ha VTN, Trieu LPT, et al. FLASH-TB: an Application of Next-Generation CRISPR to Detect Drug Resistant Tuberculosis from Direct Sputum. J Clin Microbiol, 2023, 61(4): e0163422. doi:10.1128/jcm.01634-22.
[69]	Park S, Koo B, Kim MG, et al. CADEM: Species-level detection of mycobacterial cfDNA via CRISPR for pulmonary disease diagnosis. Anal Chim Acta, 2026, 1388: 345085. doi:10.1016/j.aca.2026.345085.
[70]	Tian Z, Yan H, Zeng Y. Solid-Phase Extraction and Enhanced Amplification-Free Detection of Pathogens Integrated by Multifunctional CRISPR-Cas12a. ACS Appl Mater Interfaces, 2024, 16(12): 14445-14456. doi:10.1021/acsami.3c17039.
[71]	Cheng Y, Guo W, Wan Y, et al. Ultrasensitive Detection of Nucleic Acid and Protein at Ambient Temperature by Using an Engineered CRISPR-Cas12a-Based Digital Assay. Anal Chem, 2025, 97(33): 18355-18363. doi:10.1021/acs.analchem.5c03865. pmid: 40817853
[72]	Nguyen LT, Rananaware SR, Yang LG, et al. Engineering highly thermostable Cas12b via de novo structural analyses for one-pot detection of nucleic acids. Cell Rep Med, 2023, 4(5): 101037. doi:10.1016/j.xcrm.2023.101037.
[73]	张胜胜, 吴芳, 罗志丹, 等. CRISPR/Cas12b核酸检测试剂的冻干配方筛选与优化. 江苏海洋大学学报(自然科学版), 2023, 32(3): 43-48.
[74]	Srisuma P, Chen G, Braatz RD. Mechanistic Modeling of Continuous Lyophilization for Biopharmaceutical Manufacturing. Adv Sci (Weinh), 2025, 12(47): e11693. doi:10.1002/advs.202511693.
[75]	Srisuma P, Barbastathis G, Braatz RD. Real-time estimation of bound water concentration during lyophilization with temperature-based state observers. Int J Pharm, 2024, 665: 124693. doi:10.1016/j.ijpharm.2024.124693.
[76]	刘梅. 基于侧流层析试纸条的冻干RPA-CRISPR/Cas12a核酸即时检测方法的研究. 天津: 天津理工大学, 2023.
[77]	Wang Y, Chen H, Lin K, et al. Ultrasensitive single-step CRISPR detection of monkeypox virus in minutes with a vest-pocket diagnostic device. Nat Commun, 2024, 15(1): 3279. doi:10.1038/s41467-024-47518-8. pmid: 38627378
[78]	Cao Y, Wang J, Fan Z, et al. An extraction-free, lyophilized one-pot RAA-CRISPR assay for point-of-care testing of Haemophilus influenzae. J Clin Microbiol, 2025, 63(11): e0053525. doi:10.1128/jcm.00535-25.
[79]	Wang YM, Xu T, Duan JQ, et al. An Integrated One-Tube RPA-CRISPR/Cas13d Assay Coupled with Lateral Flow for Rapid PRRSV-1 Detection. J Agric Food Chem, 2025, 73(42): 27080-27088. doi:10.1021/acs.jafc.5c07919.
[80]	Fu J, Mo R, Li Z, et al. An extraction-free one-pot assay for rapid detection of Klebsiella pneumoniae by combining RPA and CRISPR/Cas12a. Biosens Bioelectron, 2025, 267: 116740. doi:10.1016/j.bios.2024.116740.
[81]	Drzewnioková P, Brian I, Mancin M, et al. Validation and multi-site deployment of a lyophilized qRT-PCR reagent for the molecular diagnosis of avian influenza and rabies in Sub-Saharan African regions. J Clin Microbiol, 2025, 63(8): e0008025. doi:10.1128/jcm.00080-25.
[82]	Auer A, Panzarin V, Monne I, et al. Comparative assessment of lyophilized and wet reagents for the molecular detection of H5N1 high pathogenic avian influenza virus and H9N2 low pathogenic avian influenza virus. J Virol Methods, 2023, 314: 114686. doi:10.1016/j.jviromet.2023.114686.